A Phase I, Open-label, Multicenter Study of ZL-1218 as a Single Agent and as Combination Therapy with Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Advanced Solid Tumor Malignancies
This medical study is designed to study the safety, tolerability, and pharmacokinetics of ZL-1218, a new drug that is being developed to treat advanced solid tumors. The drug will be given to patients in two ways: either as a single agent or in combination with an anti-PD-1 antibody. Anti-PD-1 antibodies are a type of immunotherapy that work by blocking a protein called PD-1, which helps cancer cells evade the immune system. By blocking PD-1, anti-PD-1 antibodies can help the immune system to attack and kill cancer cells.
Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.
For more information about the trial, click the link below:
Clinical Trial Site: Sinai
To see all available clinical trials click here.